M&A Deal Summary |
|
|---|---|
| Date | 2017-04-03 |
| Target | Vtesse |
| Sector | Life Science |
| Buyer(s) | Sucampo Pharmaceuticals |
| Sellers(s) | Bay City Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 200M USD |
| Advisor(s) | Leerink Partners (Financial) Wilmer Cutler Pickering Hale and Dorr (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 80 |
| Revenue | 115M USD (2014) |
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
| Size (of disclosed) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-07 |
R-Tech Ueno
Tokyo, Japan R-Tech Ueno Ltd. is a bio pharmaceutical company. |
Buy | $275M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 56 of 63 |
| Sector: Life Science M&A | 39 of 46 |
| Type: Add-on Acquisition M&A Deals | 29 of 31 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 53 of 60 |
| Year: 2017 M&A | 1 of 3 |
| Size (of disclosed) | 10 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-10-20 |
Merus
Utrecht, Netherlands Merus BV is a fully-integrated biotechnology company developing cancer therapeutics that combine the benefits of monoclonal antibodies with the ability of simultaneously addressing multiple targets. Merus was founded in 2003 and is based in Utercht, Netherlands. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-10 |
SynGen
Sacramento, California, United States SynGen, Inc. is a developer of products that utilize single-use sterile plastic cartridge disposables mated to dedicated, highly automated electromechanical medical devices to isolate and capture stem and progenitor cells from peripheral and umbilical cord blood, bone marrow, and adipose tissue. SynGen, Inc. was founded in 2007 and is based in Sacramento, California. |
Sell | - |
